Rebamipide Attenuates 5-Fluorouracil-Induced Small Intestinal Mucositis in a Mouse Model
- 1 January 2015
- journal article
- Published by Pharmaceutical Society of Japan in Biological & Pharmaceutical Bulletin
- Vol. 38 (2), 179-183
- https://doi.org/10.1248/bpb.b14-00400
Abstract
5-Fluorouracil (5-FU)-induced intestinal mucositis is one of the most common morbidities in chemotherapy and involves the reactive oxygen species (ROS) system, apoptosis, and inflammatory cytokines. Rebamipide exerts a mucosal-protective effect, mediated through several mechanisms. The aim of this study was to evaluate the effects of rebamipide in 5-FU-induced mouse small-intestinal mucositis. BALB/c mice were assigned randomly to four groups; (1) control group (n=10; receiving saline orally for 6 d), (2) rebamipide group (n=10; 150 mg/kg rebamipide for 6 d orally), (3) 5-FU group (n=10; 30 mg/kg 5-FU for 5 d, intraperitoneally (i.p.)), and (4) rebamipide +5-FU group (n=10; 150 mg/kg rebamipide for 6 d orally and 30 mg/kg 5-FU for 5 d, i.p.). Body weights and diarrhea scales were assessed. At day 5, the mice were sacrificed. Small intestinal tissue was used for: (1) hematoxylin and eosin (HE) staining for determination of small intestinal villi height, (2) terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) assay, (3) immunohistochemistry for inducible nitric oxide synthase (iNOS), F4/80, and transforming growth factor (TGF)-β1, (4) measurement of serum and tissue GSH levels, and (5) measurement of serum tumor necrosis factor (TNF)-α levels. Rebamipide attenuated the severity of mucosal injury reflected by body weight changes, degrees of diarrhea, and heights of villi. Rebamipide reduced the expression of iNOS and TGF-β1, apoptosis, macrophage accumulation, serum TNF-α levels, and prevented reductions in serum and tissue glutathione (GSH) levels by 5-FU administration. These results suggest that rebamipide promotes several mechanisms of mucosal protection and attenuated the 5-FU-induced mucosal injury. In conclusion, administration of rebamipide may have significant protective effects against 5-FU-induced intestinal mucositis.Keywords
This publication has 13 references indexed in Scilit:
- A review of analytical methods for the determination of 5-fluorouracil in biological matricesAnalytical and Bioanalytical Chemistry, 2010
- Small Bowel Tissue Concentration of Rebamipide: Study of Two Dosages in Healthy SubjectsJournal of Clinical Biochemistry and Nutrition, 2010
- Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damageSupportive Care in Cancer, 2006
- The pathobiology of mucositisNature Reviews Cancer, 2004
- An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignanciesTransplantation and Cellular Therapy, 2003
- Protective effect of rebamipide on indomethacin‐induced intestinal damage in ratsJournal of Gastroenterology and Hepatology, 2001
- OPC-compounds prevent oxidant-induced carbonylation and depolymerization of the F-actin cytoskeleton and intestinal barrier hyperpermeabilityFree Radical Biology & Medicine, 2001
- Treatment-induced mucositis: an old problem with new remedies.British Journal of Cancer, 1998
- Rebamipide Attenuates Indomethacin-Induced Gastric Mucosal Lesion Formation by Inhibiting Activation of Leukocytes in RatsDigestive Diseases and Sciences, 1997
- Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the ratEuropean Journal of Pharmacology, 1987